开云app官网登录入口网页版-官方正版

#cART#

34篇内容 | 1940人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2171736, encodeId=dade21e173657, content=<a href='/topic/show?id=f6435e4216a' target=_blank style='color:#2F92EE;'>#放疗#</a> <a href='/topic/show?id=170699e5621' target=_blank style='color:#2F92EE;'>#非霍奇金淋巴瘤#</a> <a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=【AJH】在R/R NHL的CART治疗中纳入放疗：梅奥多中心共识路径, objectType=article, longId=802611, objectId=2b79802611e2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medics-and-patient-on-hospital-gurney-at-PMW6NAQ.jpg, objectUrl=/article/show_article.do?id=2b79802611e2, replyNumber=0, likeNumber=82, createdTime=2023-11-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=2b79802611e2, moduleTitle=【AJH】在R/R NHL的CART治疗中纳入放疗：梅奥多中心共识路径, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2b79802611e2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1477275, encodeId=499914e727526, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=CAR-T细胞疗法Yescarta获得FDA批准用于早期治疗淋巴瘤, objectType=article, longId=723516, objectId=7576e23516c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7576e23516c3, replyNumber=0, likeNumber=86, createdTime=2022-04-06, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7576e23516c3, moduleTitle=CAR-T细胞疗法Yescarta获得FDA批准用于早期治疗淋巴瘤, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=7576e23516c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477274, encodeId=5f4e14e727465, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=Nat Med：双重靶向CART细胞对复发或难治性B-ALL儿童和年轻成人患者疗效分析, objectType=article, longId=218616, objectId=a035218616b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a035218616b0, replyNumber=0, likeNumber=87, createdTime=2021-10-16, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a035218616b0, moduleTitle=Nat Med：双重靶向CART细胞对复发或难治性B-ALL儿童和年轻成人患者疗效分析, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a035218616b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477273, encodeId=074d14e72736e, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=Int J Cancer：多西他赛+卡铂 vs 表阿霉素+环磷酰胺续贯多西他赛新辅助化疗治疗早期三阴型乳腺癌的疗效对比：多中心随机对照研究(NeoCART), objectType=article, longId=218117, objectId=5c0921811e5f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c0921811e5f, replyNumber=0, likeNumber=93, createdTime=2021-10-06, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c0921811e5f, moduleTitle=Int J Cancer：多西他赛+卡铂 vs 表阿霉素+环磷酰胺续贯多西他赛新辅助化疗治疗早期三阴型乳腺癌的疗效对比：多中心随机对照研究(NeoCART), moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5c0921811e5f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477272, encodeId=74c314e727244, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=J Gastroenterology H: 无细胞浓缩腹水回输疗法 (CART) 对肝硬化腹水患者具有良好的治疗效果, objectType=article, longId=214227, objectId=605f21422e3d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=605f21422e3d, replyNumber=0, likeNumber=91, createdTime=2021-07-16, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=605f21422e3d, moduleTitle=J Gastroenterology H: 无细胞浓缩腹水回输疗法 (CART) 对肝硬化腹水患者具有良好的治疗效果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=605f21422e3d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477271, encodeId=eaa914e72715d, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=Cancer Med：连续输注CD19-CART和BCMA CARTs可有效且安全的治疗RRMM, objectType=article, longId=210741, objectId=5562210e411f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5562210e411f, replyNumber=0, likeNumber=79, createdTime=2021-05-03, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5562210e411f, moduleTitle=Cancer Med：连续输注CD19-CART和BCMA CARTs可有效且安全的治疗RRMM, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5562210e411f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477270, encodeId=b20114e72703c, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, objectType=article, longId=206207, objectId=df2920620e11, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2920620e11, replyNumber=0, likeNumber=87, createdTime=2021-01-26, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2920620e11, moduleTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=df2920620e11)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477269, encodeId=b97714e7269b2, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=FDA暂停CAR-T疗法UCARTCS1治疗多发性骨髓瘤的临床试验, objectType=article, longId=203554, objectId=dd3d2035543d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd3d2035543d, replyNumber=0, likeNumber=59, createdTime=2020-11-21, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd3d2035543d, moduleTitle=FDA暂停CAR-T疗法UCARTCS1治疗多发性骨髓瘤的临床试验, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=dd3d2035543d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477268, encodeId=33ef14e726828, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=Mol Ther：慢病毒转导的CART-meso在晚期实体癌中的I期研究, objectType=article, longId=201443, objectId=995e20144349, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=995e20144349, replyNumber=0, likeNumber=138, createdTime=2020-10-02, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=995e20144349, moduleTitle=Mol Ther：慢病毒转导的CART-meso在晚期实体癌中的I期研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=995e20144349)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477267, encodeId=d98414e72670e, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=medRxiv：世界首例PD1敲除非病毒定点整合CART治疗淋巴瘤取得突破性成果, objectType=article, longId=201270, objectId=3ae92012e040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ae92012e040, replyNumber=0, likeNumber=93, createdTime=2020-09-28, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ae92012e040, moduleTitle=medRxiv：世界首例PD1敲除非病毒定点整合CART治疗淋巴瘤取得突破性成果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3ae92012e040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477266, encodeId=185c14e726667, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤, objectType=article, longId=198053, objectId=701319805312, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=701319805312, replyNumber=0, likeNumber=92, createdTime=2020-07-27, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=701319805312, moduleTitle=FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=701319805312)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477265, encodeId=a5e814e7265ad, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=4.56亿美元，吉利德CAR-T疗法Yescarta2019年销售业绩披露, objectType=article, longId=187885, objectId=d23418e8852c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d23418e8852c, replyNumber=0, likeNumber=154, createdTime=2020-02-14, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d23418e8852c, moduleTitle=4.56亿美元，吉利德CAR-T疗法Yescarta2019年销售业绩披露, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=d23418e8852c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477264, encodeId=9be814e7264a6, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=Cellectis的同种异体CAR-T细胞疗法（UCART）开始用于治疗复发/难治性急性髓细胞白血病患者, objectType=article, longId=186372, objectId=76531863e2f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76531863e2f1, replyNumber=0, likeNumber=81, createdTime=2020-01-18, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76531863e2f1, moduleTitle=Cellectis的同种异体CAR-T细胞疗法（UCART）开始用于治疗复发/难治性急性髓细胞白血病患者, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=76531863e2f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477263, encodeId=e04e14e726324, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿, objectType=article, longId=184904, objectId=574418490463, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=574418490463, replyNumber=0, likeNumber=79, createdTime=2019-12-19, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=574418490463, moduleTitle=百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=574418490463)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477262, encodeId=1e6914e726247, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=ASH2019：外周血白血病负荷对难治/复发急性B淋巴细胞白血病CD19-CART细胞培养及临床疗效的影响, objectType=article, longId=184476, objectId=09e41844e696, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09e41844e696, replyNumber=0, likeNumber=77, createdTime=2019-12-11, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09e41844e696, moduleTitle=ASH2019：外周血白血病负荷对难治/复发急性B淋巴细胞白血病CD19-CART细胞培养及临床疗效的影响, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=09e41844e696)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477261, encodeId=6d3714e72612a, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=第61届ASH：Kite将展示Yescarta治疗多种血液肿瘤的全新数据, objectType=article, longId=182556, objectId=c322182556d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c322182556d8, replyNumber=0, likeNumber=91, createdTime=2019-11-09, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c322182556d8, moduleTitle=第61届ASH：Kite将展示Yescarta治疗多种血液肿瘤的全新数据, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c322182556d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477260, encodeId=8a4c14e72609a, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=Procarta获得150万欧元资助用于新型抗生素的研发以抗击抗菌素耐药性, objectType=article, longId=161793, objectId=206b161e93a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=206b161e93a1, replyNumber=0, likeNumber=89, createdTime=2019-03-08, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=206b161e93a1, moduleTitle=Procarta获得150万欧元资助用于新型抗生素的研发以抗击抗菌素耐药性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=206b161e93a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477259, encodeId=bd0614e7259a2, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=加拿大批准Yescarta（Axicabtagene Ciloleucel）CAR T疗法治疗成人复发或难治性大B细胞淋巴瘤, objectType=article, longId=160891, objectId=16d216089137, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16d216089137, replyNumber=0, likeNumber=93, createdTime=2019-02-25, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16d216089137, moduleTitle=加拿大批准Yescarta（Axicabtagene Ciloleucel）CAR T疗法治疗成人复发或难治性大B细胞淋巴瘤, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=16d216089137)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477258, encodeId=ee6014e72582b, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=CLIN CANCER RES：三代CART治疗淋巴瘤和白血病, objectType=article, longId=156355, objectId=fc37156355cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc37156355cb, replyNumber=0, likeNumber=76, createdTime=2018-12-23, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc37156355cb, moduleTitle=CLIN CANCER RES：三代CART治疗淋巴瘤和白血病, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=fc37156355cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477257, encodeId=267f14e7257b2, content=<a href='/topic/show?id=429a41149d' target=_blank style='color:#2F92EE;'>#cART#</a>, objectTitle=【2018 CSCO】黄慧强教授：CAR-T产品Yescarta在复发/难治NHL的治疗中处于领先地位, objectType=article, longId=149577, objectId=a4e21495e77d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4e21495e77d, replyNumber=0, likeNumber=75, createdTime=2018-09-27, rootId=0, userName=ms2999106592497887, userId=46987366013, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4e21495e77d, moduleTitle=【2018 CSCO】黄慧强教授：CAR-T产品Yescarta在复发/难治NHL的治疗中处于领先地位, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a4e21495e77d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

cART

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#放疗# #非霍奇金淋巴瘤# #cART#

【AJH】在R/R NHL的CART治疗中纳入放疗：梅奥多中心共识路径

2023-11-29发表于上海

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

CAR-T细胞疗法Yescarta获得FDA批准用于早期治疗淋巴瘤

2022-04-06

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

Nat Med：双重靶向CART细胞对复发或难治性B-ALL儿童和年轻成人患者疗效分析

2021-10-16

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

Int J Cancer：多西他赛+卡铂 vs 表阿霉素+环磷酰胺续贯多西他赛新辅助化疗治疗早期三阴型乳腺癌的疗效对比：多中心随机对照研究(NeoCART)

2021-10-06

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

J Gastroenterology H: 无细胞浓缩腹水回输疗法 (CART) 对肝硬化腹水患者具有良好的治疗效果

2021-07-16

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

Cancer Med：连续输注CD19-CART和BCMA CARTs可有效且安全的治疗RRMM

2021-05-03

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）

2021-01-26

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

FDA暂停CAR-T疗法UCARTCS1治疗多发性骨髓瘤的临床试验

2020-11-21

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

Mol Ther：慢病毒转导的CART-meso在晚期实体癌中的I期研究

2020-10-02

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

medRxiv：世界首例PD1敲除非病毒定点整合CART治疗淋巴瘤取得突破性成果

2020-09-28

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤

2020-07-27

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

4.56亿美元，吉利德CAR-T疗法Yescarta2019年销售业绩披露

2020-02-14

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

Cellectis的同种异体CAR-T细胞疗法（UCART）开始用于治疗复发/难治性急性髓细胞白血病患者

2020-01-18

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿

2019-12-19

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

ASH2019：外周血白血病负荷对难治/复发急性B淋巴细胞白血病CD19-CART细胞培养及临床疗效的影响

2019-12-11

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

第61届ASH：Kite将展示Yescarta治疗多种血液肿瘤的全新数据

2019-11-09

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

Procarta获得150万欧元资助用于新型抗生素的研发以抗击抗菌素耐药性

2019-03-08

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

加拿大批准Yescarta（Axicabtagene Ciloleucel）CAR T疗法治疗成人复发或难治性大B细胞淋巴瘤

2019-02-25

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

CLIN CANCER RES：三代CART治疗淋巴瘤和白血病

2018-12-23

ms2999106592497887 (审核中...)

前往app查看评论内容

#cART#

【2018 CSCO】黄慧强教授：CAR-T产品Yescarta在复发/难治NHL的治疗中处于领先地位

2018-09-27

科室
- - 订阅+
  - 更多科室
工具
服务